Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Hereditary angioedema (HAE) is an autosomal disorder characterized by low levels of functional C1 esterase inhibitor protein. Purified concentrate of C1 esterase inhibitors are used in HAE affected patients for the prophylactic and acute attack treatment of HAE. Several plasma protease C1-inhibitors such as Cinryze, Firazyr, Kalbitor, and Berinet have been approved for the prophylactic and acute attack treatment of hereditary angioedema.

Global plasma protease C1-inhibitor treatment market is estimated to be valued at US$ 3,289.5 million in 2020 and is expected to exhibit a CAGR of 18.2% during the forecast period (2020-2027).

Figure 1. Global Plasma Protease C1-inhibitor Treatment Market Share (%), by Drug Type, 2020

Plasma Protease C1-inhibitor Treatment  | Coherent Market Insights

Global Plasma Protease C1-inhibitor Treatment Market – Drivers

The increasing focus of biopharmaceutical companies on development of effective plasma protease C1-inhibitor treatment drugs/therapy treating various health conditions such as HAE, diabetic macular edema (DME), and others, is expected to drive growth of the plasma protease C1-inhibitor treatment market. Several kallikrein inhibitor therapies are currently in preclinical and clinical development stages. For instance, in September 2019, Oxurion released positive topline data from a phase 1 study of THR-149, a plasma kallikrein inhibitor for the treatment of diabetic macular edema (DME). Moreover, in December 2019, KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced results of the Phase 2 clinical trial evaluating the use of KVD001 in patients with diabetic macular edema (DME).

Furthermore, adoption of inorganic growth strategies such as partnerships and collaborations, in order to develop innovative protease C1-inhibitor treatment is significantly contributing to the growth of global plasma protease C1-inhibitor treatment market. For instance, in October 2017, KalVista Pharmaceuticals, Inc. entered into a collaboration agreement with Merck, known as MSD outside the U.S. and Canada for KVD001 (investigational plasma kallikrein inhibitors). The company’s investigational intravitreal (IVT) injection candidate is currently in development for potential treatment of diabetic macular edema (DME).

request-sample

Plasma Protease C1-inhibitor Treatment Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 3,289.5 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 18.2% 2027 Value Projection: US$ 10,603.4 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of the Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: C1-inhibitors, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist.
  • By Dosage: Lyophilized, Injectable.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals, Inc.

Growth Drivers:
  • Increasing product approvals/ launches
  • Increasing research and development
  • Adoption of inorganic strategies
Restraints & Challenges:
  • The rare occurrence of the HAE
  • Lower diagnosis rate

Global Plasma Protease C1-inhibitor Treatment Market - Restraints

However, the rare occurrence of the HAE makes it difficult for efficient diagnosis and opting alternative therapies to control the disease are the major factors that are expected to restrain the plasma protease c1-inhibitor treatment market growth over the forecast period.

Figure 2. Global Plasma Protease C1-inhibitor Treatment Market Share (%), by Region, 2020

Plasma Protease C1-inhibitor Treatment  | Coherent Market Insights

Global Plasma Protease C1-inhibitor Treatment Market - Regional Analysis

On the basis of region, the global plasma protease C1-inhibitor treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America plasma protease C1-inhibitor treatment market is expected to exhibit significant growth during the forecast period, owing to increasing approvals of novel therapies by the regulatory agencies such as the U.S. Food and Drug Administration. For instance, in 2014, the U.S. FDA approved Pharming Healthcare’s Ruconest, a recombinant C1-esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with HAE.

Key Players:

Key players operating in the global plasma protease C1-inhibitor treatment market include CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals, Inc.

C1-inhibitor (C1-H) belongs to the superfamily of serine protease inhibitors. C1-inhibitors controls the activation of the C1 complex. It forms a proteolytically inactive stoichiometric complex with the C1r or C1s proteases. It also plays an important role in regulating important physiological pathways including complement activation, blood coagulation, fibrinolysis, and generation of kinins. It is the most efficient inhibitor of FXIIa factors and also inhibits chymotrypsin and kallikrein.

Market Dynamics

Hereditary angioedema (HAE) is the disease condition characterized by the C1 esterase inhibitor deficiency. According to reported data by National Center for Biotechnology Information in 2013, the estimated prevalence of HAE in the general population is between 1 in 10,000 and 1 in 150,000 individuals worldwide. Cinryze, a pharmaceutical-grade C1-inhibitor, was approved by U.S.FDA for the treatment of HAE in 2008. Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product; it has been approved for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. Thus, the increasing trend of using plasma-derived C1 esterase inhibitor products in HAE treatment is expected to drive growth of the global plasma protease C1-inhibitor treatment market.

Key features of the study:

  • This report provides in-depth analysis of the global plasma protease C1-inhibitor treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020-2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global plasma protease C1-inhibitor treatment market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key players operating in the global plasma protease C1-inhibitor treatment market include CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals, Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global plasma protease C1-inhibitor treatment market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plasma protease C1-inhibitor treatment market.

Detailed Segmentation:

  • Global Plasma Protease C1-inhibitor Treatment Market, By Drug Type:
    • C1-inhibitors
    • Kallikrein Inhibitor
    • Selective Bradykinin B2 Receptor Antagonist
  • Global Plasma Protease C1-inhibitor Treatment Market, By Dosage:
    • Lyophilized
    • Injectable
  • Global Plasma Protease C1-inhibitor Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Plasma Protease C1-inhibitor Treatment Market, By Region:
    • North America
      • By Drug Type:
        • C1-inhibitors
        • Kallikrein Inhibitor
        • Selective Bradykinin B2 Receptor Antagonist
      • By Dosage:
        • Lyophilized
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drug Type:
        • C1-inhibitors
        • Kallikrein Inhibitor
        • Selective Bradykinin B2 Receptor Antagonist
      • By Dosage:
        • Lyophilized
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Type:
        • C1-inhibitors
        • Kallikrein Inhibitor
        • Selective Bradykinin B2 Receptor Antagonist
      • By Dosage:
        • Lyophilized
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies    
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type:
        • C1-inhibitors
        • Kallikrein Inhibitor
        • Selective Bradykinin B2 Receptor Antagonist
      • By Dosage:
        • Lyophilized
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Type:
        • C1-inhibitors
        • Kallikrein Inhibitor
        • Selective Bradykinin B2 Receptor Antagonist
      • By Dosage:
        • Lyophilized
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type:
        • C1-inhibitors
        • Kallikrein Inhibitor
        • Selective Bradykinin B2 Receptor Antagonist
      • By Dosage:
        • Lyophilized
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles:
    • CSL Behring LLC *
      • Company Overview
      • Clinical Trial Phase Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Takeda Pharmaceutical Company Limited
    • Ionis Pharmaceuticals, Inc.
    • Pharming Technologies B.V.
    • Centogene AG
    • BioCryst Pharmaceuticals
    • KalVista Pharmaceuticals, Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Dosage
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Impact Analysis
    • Market Opportunities
    • Collaboration and acquisition
  4. Plasma Protease C1-inhibitor Treatment Market, Impact of COVID-19 Pandemic
    • Post COVID-19 Impact
    • COVID-19 Impact on Research and Development Activities
    • Demand and Supply Analysis
    • Overall impact on manufacturing industry
  5. Plasma Protease C1-inhibitor Treatment Market, By Drug Type, 2016-2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        • C1-inhibitors
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Kallikrein Inhibitor
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Selective Bradykinin B2 Receptor Antagonist
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  6. Plasma Protease C1-inhibitor Treatment Market, By Dosage, 2016-2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        • Lyophilized
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Injectable
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  7. Plasma Protease C1-inhibitor Treatment Market, By Distribution Channel, 2016-2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        • Hospital Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Retail Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Online Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  8. Plasma Protease C1-inhibitor Treatment Market, By Region, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Country, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Countries, 2017–2027
    • North America
      • Introduction
      • Market Size and Forecast, By Drug Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Dosage, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, By Drug Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Dosage, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, By Drug Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Dosage, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • Germany
        • U.K.
        • France       
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, By Drug Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Dosage, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, By Drug Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Dosage, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, By Drug Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Dosage, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016–2027 (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Company Profiles
      • CSL Behring LLC.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Takeda Pharmaceutical Company Limited
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Ionis Pharmaceuticals, Inc.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pharming Technologies B.V.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Centogene AG
        •  Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • BioCryst Pharmaceuticals
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • KalVista Pharmaceuticals, Inc.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies

 *Browse 32 market data tables and 30 figures on " Plasma Protease C1-inhibitor Treatment Market – Global forecast to 2027”.

Frequently Asked Questions

The global plasma protease C1-inhibitor treatment market is estimated to be valued at US$ 3,289.5 million in 2020 and is expected to exhibit a CAGR of 18.2% between 2020 and 2027.
Increasing products approvals, rising research and development, adoption of inorganic growth strategies by key players are the factors that are driving growth of the global plasma protease C1-inhibitor treatment market.
CI-inhibitors segment is estimated to account for major share in the plasma protease C1-inhibitor treatment market during the forecast period.
Lyophilized segment is estimated to hold major market share in 2020, owing to increasing focus of pharmaceutical companies on development of lyophilized plasma protease C1-inhibitor.
North America is estimated to generate highest revenue share in 2020 in the global plasma protease C1-inhibitor treatment market during the forecast period.
The rare occurrence of the HAE is expected to hamper growth of the global plasma protease C1-inhibitor treatment market during the forecast period.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner